Bevacizumab


Bevacizumab, sold under the trade name Avastin, is a humanized monoclonal antibody, which can be used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. For age-related macular degeneration, it is given by injection into the eye. It is designed to block a protein called vascular endothelial growth factor (VEGF). Normal cells make VEGF, but some cancer cells make too much VEGF. Blocking VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors.

Figure 1. A schematic of the proposed mechanism of action of benefit from antiangiogenic therapy. (Sara M. Tolaney, 2015)

Bevacizumab was originally derived from a mouse monoclonal antibody generated from mice immunized with the 165-residue-form of recombinant human vascular endothelial growth factor. It was humanized by retaining the binding region and replacing the rest with a human full light chain and a human truncated IgG1 heavy chain, with some other substitutions. Bevacizumab was approved for medical use in the United States in 2004. Bevacizumab comes off-patent in 2018 (extended expiry) and already many companies are developing biosimilar versions.

Bevacizumab Biosimilars Analysis at Creative Proteomics
Creative Proteomics is experienced in the analysis of different variants of Avastin originators and biosimilars. To support the development of Avastin biosimilars or biobetters, Creative Proteomics has set up an analysis program, including:

Table 1. Bevacizumab Biosimilars Analysis at Creative Proteomics

ServicesAnalysis Program
Protein quantification
  • Quantitative amino acid assay (AAA)
  • Extinction coefficient determination
  • Mass spectrometry-based quantification by multiple reaction monitoring (MRM)
Structural characterization and confirmation
  • Amino acid sequence
  • Amino acid composition
  • N- & C-terminal sequencing
  • Peptide mapping
  • S-S bridge analysis
  • Glycosylation analysis
  • Post-translational modifications (PTMs)
Physicochemical properties
  • Molecular weight or size
  • Isoform pattern
  • Extinction coefficient
  • Electrophoretic patterns
  • Liquid chromatographic patterns
  • Spectroscopic profiles
Process and product-related impurities
  • Host cell proteins
  • Truncated forms
  • Protein aggregation

The research of bevacizumab biosimilars has great value and Creative Proteomics is the best partner for biosimilars analysis to optimize the biosimilars development and increase success rate. If you have any questions about biosimilars analysis, please feel free to contact us.

Reference:
1. Sara M. Tolaney. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients Abatacept: a t-cell co-stimulation modulator for the treatment of rheumatoid arthritis. Proc Natl Acad Sci U S A, 2015,112(46):14325-14330.


INQUIRY
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Inquiry

Online Inquiry

Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.

Related Services

Protein Therapeutics Analysis

Bioanalysis Services

Analysis Services

Stay in contact

  • 45-1 Ramsey Road, Shirley, NY 11967, USA
  • Tel: 1-631-275-3058
  • Fax: 1-631-614-7828
  • Email:
© 2008-2019 Creative Proteomics. All rights reserved.